Table 3.

Study population and treatment group characteristics

	Home-based pdC1-INH (N = 20)	Home-based icatibant (N = 11)	Hospital-based pdC1-INH (N = 8)	Overall (N = 39)
Gender, N (%)
Female	13 (65.0)	8 (72.7)	5 (62.5)	26 (66.6)
Male	7 (35.0)	3 (27.3)	3 (37.5)	13 (33.4)
Age, mean (±SD)	33.0 (±18.7)	37.0 (±11.7)	31.0 (±20.4)	33.7 (±17.1)
Disease severity score, mean (±SD)	7.8 (±1.7)	6.9 (±1.6)	6.6 (±1.5)	7.3 (±1.7)

pdC1-INH plasma-derived C1-esterase inhibitor concentrate, SD standard deviation